FDA approves Alcon's BRYTLY, a new apraclonidine eye drop formulation
The agency cleared the solution under a new drug application on October 16, 2026, as a new formulation rather than a novel active ingredient.
The U.S. Food and Drug Administration approved BRYTLY, a formulation of apraclonidine made by Alcon Laboratories, Inc., with an action date of October 16, 2026. The submission was processed as application number NDA220341, original submission 1, and was granted standard review priority.1
The product is formulated as a solution in drops form, with the active ingredient apraclonidine at a strength of 0.125 percent.1
Regulatory records classify this clearance under submission class Type 5, which covers a new formulation or new manufacturer rather than a new molecular entity.1 The submission status is listed as approved, with a submission status date of October 16, 2026.1
The FDA's drug approval database shows two associated documents dated October 16, 2026: a product label and an approval letter, both posted to the agency's drug database under the same filing date.1
No additional details on indicated use, dosing regimen, clinical trial data, or commercial launch timing were included in the FDA database record reviewed for this report. Readers seeking information on the clinical basis for approval or planned marketing should consult the label and approval letter directly, as those documents were not summarized in the source record.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.